An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)

2024-511963-28-00 Protocol CSET N°2021/3339 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 19 Dec 2023 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 2 sites · Protocol CSET N°2021/3339

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 78
Countries 1
Sites 2

Neoadjuvant therapy in locally-advanced rectal cancer

Key facts

Sponsor
Institut Gustave Roussy
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Pathological Conditions, Signs and Symptoms [C23], Diseases [C] - Digestive System Diseases [C06], Diseases [C] - Immune System Diseases [C20]
Trial duration
19 Dec 2023 → ongoing
Decision date (initial)
2024-06-10
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-511963-28-00
EudraCT number
2021-005363-43

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Neoadjuvant therapy in locally-advanced rectal cancer

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Institut Gustave Roussy

Sponsor organisation
Institut Gustave Roussy
Address
114 Rue Edouard Vaillant
City
Villejuif
Postcode
94800
Country
France

Scientific contact point

Organisation
Institut Gustave Roussy
Contact name
Pr Eric Deutsch

Public contact point

Organisation
Institut Gustave Roussy
Contact name
Pr Eric Deutsch

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruitment ended 78 2
Rest of world 0

Investigational sites

France

2 sites · Ongoing, recruitment ended
Centre Leon Berard
ONCOLOGIE, 28 Rue Laennec, 69008, Lyon
Institut Gustave Roussy
ONCOLOGIE, 114 Rue Edouard Vaillant, 94800, Villejuif

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2023-12-19 2023-12-19 2025-05-21

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-16 France Acceptable
2024-06-10
2024-06-10